IDO1: An important immunotherapy target in cancer treatment

International Immunopharmacology

Volumn 47, Issue , 2017, Pages 70-77

  Fangxuan, Li ^a,b,c,d   Rupeng, Zhang ^a,b,c,d   Shixia, Li ^a,b,c,d   Juntian, Liu ^a,b,c,d  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Cancer Hosipital   (China)

^c KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^d Key Laboratory of Cancer Prevention and Therapy   (China)

Author keywords

Dendritic cells; Indoleamine 2,3 dioxigenase; Indoximod; Regulator T cells; Tumor

Indexed keywords

4 AMINO N (3 CHLORO 4 FLUOROPHENYL) N' HYDROXY 1,2,5 OXADIAZOLE 3 CARBOXIMIDAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; INDOXIMOD; JANUS KINASE; KYNURENINE; MAMMALIAN TARGET OF RAPAMYCIN; NLG 919; PROTEIN KINASE C; STAT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRYPTOPHAN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; ALKYLATING AGENT; EIF2AK4 PROTEIN, HUMAN; INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN; PROTEIN SERINE THREONINE KINASE; TARGET OF RAPAMYCIN KINASE;

ANTIGEN PRESENTING CELL; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DRUG TARGETING; HUMAN; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE DIFFERENTIATION; METABOLITE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; PROCEDURES; TUMOR ESCAPE;

ANTINEOPLASTIC AGENTS, ALKYLATING; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; MOLECULAR TARGETED THERAPY; NEOPLASMS; NF-KAPPA B; PROTEIN-SERINE-THREONINE KINASES; T-LYMPHOCYTES, REGULATORY; TOR SERINE-THREONINE KINASES; TUMOR ESCAPE;

EID: 85016415154     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2017.03.024     Document Type: Review

References (73)

1. [1] Lob, S., Konigsrainer, A., Zieker, D., et al. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism [J]. Cancer Immunol. Immunother. 58:1 (2009), 153–157.
2. [2] Lob, S., Konigsrainer, A., Rammensee, H.G., et al. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? [J]. Nat. Rev. Cancer 9:6 (2009), 445–452.
3. [3] Breda, C., Sathyasaikumar, K.V., Sograte, I.S., et al. Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites [J]. Proc. Natl. Acad. Sci. U. S. A. 113:19 (2016), 5435–5440.
4. [4] Dai, W., Gupta, S.L., Molecular cloning, sequencing and expression of human interferon-gamma-inducible indoleamine 2,3-dioxygenase cDNA [J]. Biochem. Biophys. Res. Commun. 168:1 (1990), 1–8.
5. [5] Thackray, S.J., Mowat, C.G., Chapman, S.K., Exploring the mechanism of tryptophan 2,3-dioxygenase [J]. Biochem. Soc. Trans. 36 (2008), 1120–1123 (Pt 6).
6. [6] Uyttenhove, C., Pilotte, L., Theate, I., et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase [J]. Nat. Med. 9:10 (2003), 1269–1274.
7. [7] Fallarino, F., Grohmann, U., Vacca, C., et al. T cell apoptosis by kynurenines [J]. Adv. Exp. Med. Biol. 527 (2003), 183–190.
8. [8] Munn, D.H., Sharma, M.D., Baban, B., et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase [J]. Immunity 22:5 (2005), 633–642.
9. [9] McGaha, T.L., IDO-GCN2 and autophagy in inflammation [J]. Oncotarget 6:26 (2015), 21771–21772.
10. [10] Metz, R., Rust, S., Duhadaway, J.B., et al. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by D-1-methyl-tryptophan [J]. Oncoimmunology 1:9 (2012), 1460–1468.
11. [11] Liu, H., Liu, L., Liu, K., et al. Reduced cytotoxic function of effector CD8 + T cells is responsible for indoleamine 2,3-dioxygenase-dependent immune suppression [J]. J. Immunol. 183:2 (2009), 1022–1031.
12. [12] Frumento, G., Rotondo, R., Tonetti, M., et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase [J]. J. Exp. Med. 196:4 (2002), 459–468.
13. [13] Molano, A., Illarionov, P.A., Besra, G.S., et al. Modulation of invariant natural killer T cell cytokine responses by indoleamine 2,3-dioxygenase [J]. Immunol. Lett. 117:1 (2008), 81–90.
14. [14] Wang, D., Saga, Y., Mizukami, H., et al. Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy [J]. Int. J. Oncol. 40:4 (2012), 929–934.
15. [15] Mezrich, J.D., Fechner, J.H., Zhang, X., et al. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells [J]. J. Immunol. 185:6 (2010), 3190–3198.
16. [16] Favre, D., Mold, J., Hunt, P.W., et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease [J]. Sci Transl Med 2:32 (2010), 32r–36r.
17. [17] Gandhi, R., Kumar, D., Burns, E.J., et al. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells [J]. Nat. Immunol. 11:9 (2010), 846–853.
18. [18] Jenabian, M.A., Patel, M., Kema, I., et al. Distinct tryptophan catabolism and Th17/Treg balance in HIV progressors and elite controllers [J]. PLoS One, 8(10), 2013, e78146.
19. [19] Sharma, M.D., Baban, B., Chandler, P., et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase [J]. J. Clin. Invest. 117:9 (2007), 2570–2582.
20. [20] Puccetti, P., Fallarino, F., Generation of T cell regulatory activity by plasmacytoid dendritic cells and tryptophan catabolism [J]. Blood Cells Mol. Dis. 40:1 (2008), 101–105.
21. [21] Orabona, C., Grohmann, U., Belladonna, M.L., et al. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86 [J]. Nat. Immunol. 5:11 (2004), 1134–1142.
22. [22] Dejean, A.S., Beisner, D.R., Ch'En, I.L., et al. Transcription factor Foxo3 controls the magnitude of T cell immune responses by modulating the function of dendritic cells [J]. Nat. Immunol. 10:5 (2009), 504–513.
23. [23] Gajewski, T.F., Schreiber, H., Fu, Y.X., Innate and adaptive immune cells in the tumor microenvironment [J]. Nat. Immunol. 14:10 (2013), 1014–1022.
24. [24] Mellor, A.L., Baban, B., Chandler, P., et al. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion [J]. J. Immunol. 171:4 (2003), 1652–1655.
25. [25] Munn, D.H., Sharma, M.D., Hou, D., et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes [J]. J. Clin. Invest. 114:2 (2004), 280–290.
26. [26] Della, C.M., Carlomagno, S., Frumento, G., et al. The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function [J]. Blood 108:13 (2006), 4118–4125.
27. [27] Fruci, D., Lo, M.E., Cifaldi, L., et al. T and NK cells: two sides of tumor immunoevasion [J]. J. Transl. Med., 11, 2013, 30.
28. [28] Salazar, A., Gonzalez-Rivera, B.L., Redus, L., et al. Indoleamine 2,3-dioxygenase mediates anhedonia and anxiety-like behaviors caused by peripheral lipopolysaccharide immune challenge [J]. Horm. Behav. 62:3 (2012), 202–209.
29. [29] Niinisalo, P., Raitala, A., Pertovaara, M., et al. Indoleamine 2,3-dioxygenase activity associates with cardiovascular risk factors: the health 2000 study [J]. Scand. J. Clin. Lab. Invest. 68:8 (2008), 767–770.
30. [30] Mbongue, J.C., Nicholas, D.A., Torrez, T.W., et al. The role of indoleamine 2, 3-dioxygenase in immune suppression and autoimmunity [J]. Vaccines (Basel) 3:3 (2015), 703–729.
31. [31] Brandacher, G., Perathoner, A., Ladurner, R., et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells [J]. Clin. Cancer Res. 12:4 (2006), 1144–1151.
32. [32] Ben-Haj-Ayed, A., Moussa, A., Ghedira, R., et al. Prognostic value of indoleamine 2,3-dioxygenase activity and expression in nasopharyngeal carcinoma [J]. Immunol. Lett. 169 (2016), 23–32.
33. [33] Muller, A.J., DuHadaway, J.B., Chang, M.Y., et al. Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion [J]. Cancer Immunol. Immunother. 59:11 (2010), 1655–1663.
34. [34] Li, F., Huang, J., Li, S., et al. The subsets of dendritic cells and memory T cells correspond to indoleamine 2,3-dioxygenase in stomach tumor microenvironment [J]. Tumour Biol. 35:9 (2014), 8691–8698.
35. [35] Taylor, M.W., Feng, G.S., Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism [J]. FASEB J. 5:11 (1991), 2516–2522.
36. [36] Balachandran, V.P., Cavnar, M.J., Zeng, S., et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido [J]. Nat. Med. 17:9 (2011), 1094–1100.
37. [37] Muller, A.J., DuHadaway, J.B., Chang, M.Y., et al. Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion [J]. Cancer Immunol. Immunother. 59:11 (2010), 1655–1663.
38. [38] Fallarino, F., Grohmann, U., Puccetti, P., Indoleamine 2,3-dioxygenase: from catalyst to signaling function [J]. Eur. J. Immunol. 42:8 (2012), 1932–1937.
39. [39] Smith, C., Prendergast, G.C., Inflammatory programming and immune modulation in cancer by IDO [J]. Atlas of Genetics & Cytogenetics in Oncology & Haematology, 12, 2013.
40. [40] Scheler, M., Wenzel, J., Tuting, T., et al. Indoleamine 2,3-dioxygenase (IDO): the antagonist of type I interferon-driven skin inflammation? [J]. Am. J. Pathol. 171:6 (2007), 1936–1943.
41. [41] Mellor, A.L., Baban, B., Chandler, P.R., et al. Cutting edge: CpG oligonucleotides induce splenic CD19 + dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN type 1 signaling [J]. J. Immunol. 175:9 (2005), 5601–5605.
42. [42] Mayer, E., Holzl, M., Ahmadi, S., et al. CTLA4-Ig immunosuppressive activity at the level of dendritic cell/T cell crosstalk [J]. Int. Immunopharmacol. 15:3 (2013), 638–645.
43. [43] Puccetti, P., On watching the watchers: IDO and type I/II IFN [J]. Eur. J. Immunol. 37:4 (2007), 876–879.
44. [44] Muller, A.J., DuHadaway, J.B., Donover, P.S., et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy [J]. Nat. Med. 11:3 (2005), 312–319.
45. [45] Litzenburger, U.M., Opitz, C.A., Sahm, F., et al. Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AhR [J]. Oncotarget 5:4 (2014), 1038–1051.
46. [46] Pan, K., Wang, H., Chen, M.S., et al. Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma [J]. J. Cancer Res. Clin. Oncol. 134:11 (2008), 1247–1253.
47. [47] Hara, T., Matsumoto, T., Shibata, Y., et al. Prognostic value of the combination of serum L-kynurenine level and indoleamine 2,3-dioxygenase mRNA expression in acute myeloid leukemia [J]. Leuk Lymphoma, 2016, 1–4.
48. [48] Nelson, B.H., IDO and outcomes in ovarian cancer [J]. Gynecol. Oncol. 115:2 (2009), 179–180.
49. [49] Ino, K., Yamamoto, E., Shibata, K., et al. Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival [J]. Clin. Cancer Res. 14:8 (2008), 2310–2317.
50. [50] Witkiewicz, A.K., Costantino, C.L., Metz, R., et al. Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target [J]. J. Am. Coll. Surg. 208:5 (2009), 781–787 (787-789).
51. [51] Creelan, B.C., Antonia, S., Bepler, G., et al. Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in stage III non-small cell lung cancer [J]. Oncoimmunology, 2(3), 2013, e23428.
52. [52] Levina, V., Su, Y., Gorelik, E., Immunological and nonimmunological effects of indoleamine 2,3-dioxygenase on breast tumor growth and spontaneous metastasis formation [J]. Clin Dev Immunol, 2012, 2012, 173029.
53. [53] Liu, H., Shen, Z., Wang, Z., et al. Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma [J]. Sci Rep, 6, 2016, 21319.
54. [54] Okamoto, A., Nikaido, T., Ochiai, K., et al. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells [J]. Clin. Cancer Res. 11:16 (2005), 6030–6039.
55. [55] Maleki, V.S., Chen, D., Di Cresce, C., et al. IDO downregulation induces sensitivity to Pemetrexed, gemcitabine, FK866, and Methoxyamine in human cancer cells [J]. PLoS One, 10(11), 2015, e143435.
56. [56] Zhai, L., Spranger, S., Binder, D.C., et al. Molecular pathways: targeting IDO1 and other tryptophan dioxygenases for cancer immunotherapy [J]. Clin. Cancer Res. 21:24 (2015), 5427–5433.
57. [57] Hoffman, R.M., Tumor growth control with IDO-silencing salmonella—letter [J]. Cancer Res., 73(14), 2013, 4591.
58. [58] Soliman, H.H., Antonia, S., Sullivan, D., et al. Overcoming tumor antigen anergy in human malignancies using the novel indeolamine 2,3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-D-tryptophan (1MT) [J]. J. Clin. Oncol., 2009.
59. [59] Beatty, G.L., O'Dwyer, P.J., Clark, J., et al. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies [J]. J. Clin. Oncol. 31:15 (2013), 1904–1911.
60. [60] Takamatsu, M., Hirata, A., Ohtaki, H., et al. Inhibition of indoleamine 2,3-dioxygenase 1 expression alters immune response in colon tumor microenvironment in mice [J]. Cancer Sci. 106:8 (2015), 1008–1015.
61. [61] Hou, D.Y., Muller, A.J., Sharma, M.D., et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses [J]. Cancer Res. 67:2 (2007), 792–801.
62. [62] Inaba, T., Ino, K., Kajiyama, H., et al. Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy [J]. Gynecol. Oncol. 117:3 (2010), 423–428.
63. [63] Salvadori, M.L., Da, C.B.P., Gebrim, L.H., et al. Effect of the association of 1-methyl-DL-tryptophan with paclitaxel on the expression of indoleamine 2,3-dioxygenase in cultured cancer cells from patients with breast cancer [J]. Med. Oncol., 32(11), 2015, 248.
64. [64] Jackson, E., Dees, E.C., Kauh, J.S., et al. A phase I study of indoximod in combination with docetaxel in metastatic solid tumors [J]. Journal of Clinical Oncology, 31(15), 2013.
65. [65] Soliman, H.H., Jackson, E., Neuger, T., et al. A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors [J]. Oncotarget 5:18 (2014), 8136–8146.
66. [66] Hamid, O., Schmidt, H., Nissan, A., et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma [J]. J. Transl. Med., 9, 2011, 204.
67. [67] Weber, J., Immune checkpoint proteins: a new therapeutic paradigm for cancer–preclinical background: CTLA-4 and PD-1 blockade [J]. Semin. Oncol. 37:5 (2010), 430–439.
68. [68] Soliman, H.H., Minton, S.E., Han, H.S., et al. A phase I study of ad.p53 DC vaccine in combination with indoximod in metastatic solid tumors [J]. Journal of Clinical Oncology, 31(15), 2013.
69. [69] Zitvogel, L., Kroemer, G., Targeting PD-1/PD-L1 interactions for cancer immunotherapy [J]. Oncoimmunology 1:8 (2012), 1223–1225.
70. [70] Jaroslawski, S., Caban, A., Toumi, M., Sipuleucel-T (Provenge (R)): autopsy of an innovative change of paradigm in cancer treatment [J]. Value Health, 18(7), 2015, A479.
71. [71] Gibney, G.T., Hamid, O., Gangadhar, T.C., et al. Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma [J]. J. Clin. Oncol., 2014.
72. [72] Pol, J., Bloy, N., Obrist, F., et al. Trial watch: DNA vaccines for cancer therapy [J]. Oncoimmunology, 3(1), 2014, e28185.
73. [73] Aranda, F., Vacchelli, E., Obrist, F., et al. Trial watch: toll-like receptor agonists in oncological indications [J]. Oncoimmunology, 3, 2014, e29179.